clinical trial · NCT07340814
A Long-term Follow-up Study of Patients Who Received MB-105
Any Patient Treated With MB-105MB-105
brief summary
This study is to fulfil the regulatory requirement for 15-year follow-up for patients treated with MB-105 in any study
started
Feb 27, 2026
primary completion
Oct 15, 2040
completion
Oct 15, 2040
last updated
Jan 14, 2026
detailed description
This study is for long term follow up of efficacy and safety for any patient treated with MB-105 who has consented to joining the LTFU study. There are no exclusion criteria.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol